MIRA Pharmaceuticals Discusses With Memorial Sloan Kettering To Collaborate On A Preclinical Cancer Pain Model Utilizing The Co's Novel Oral Ketamine Analog
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals is in advanced discussions with Memorial Sloan Kettering Cancer Center to initiate a preclinical study on its novel oral ketamine analog, Ketamir-2, for treating cancer-related pain and depression. This collaboration could validate the potential of Ketamir-2 beyond its current preclinical studies for other disorders.
May 21, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals is in advanced discussions with Memorial Sloan Kettering Cancer Center to study its novel oral ketamine analog, Ketamir-2, for cancer-related pain and depression. This collaboration could validate the potential of Ketamir-2 beyond its current preclinical studies for other disorders.
The collaboration with a prestigious institution like Memorial Sloan Kettering Cancer Center could significantly validate MIRA's Ketamir-2, potentially increasing investor confidence and driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100